More than one dozen novel microbes identified for row crops suffering from extreme weather conditions Tel Aviv and Rehovot, Israel; July 17, 2024 – ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, and Lavie Bio Ltd., a leading ag-biologicals company and subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), today announced
Read moreLavie Bio successfully completed testing of Yalos™ for winter wheat and will commence sales across the US for the 2024-2025 season Rehovot, Israel – July 2nd, 2024 – Lavie Bio Ltd., a leading ag-biologicals company and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), is pleased to announce the commercial expansion of its
Read moreRehovot, Israel – March 19, 2024 —Lavie Bio Ltd., a leading ag-biologicals company that develops microbiome-based, computational-driven bio-stimulant and bio-pesticide novel products and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), announced today that it is extending its joint validation trials for its biofungicides conducted by Bayer AG, a global leader in the agriculture
Read moreRehovot, Israel – March 13, 2024 — Lavie Bio Ltd., a leading ag-biologicals company that develops microbiome-based, computational-driven bio-stimulant and bio-pesticide novel products and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), today announced that Ceres Global Ag Corp. (“Ceres”) a global agricultural, energy and industrial products merchandising and supply chain company, has chosen
Read moreThe payment completes the $5M advance payment received under the licensing agreement for bio-fungicide product candidates REHOVOT, ISRAEL – February 28, 2024 – Lavie Bio Ltd., a leading ag-biologicals company that develops microbiome-based, computational-driven bio-stimulant and bio-pesticide novel products, and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), announced that it has successfully
Read moreAgreement reinforces both companies’ commitment to developing and bringing innovative biological solutions to farmers Basel, Switzerland and Rehovot, Israel – February 20, 2024 – Syngenta Crop Protection, a leader in agricultural innovation, and Lavie Bio Ltd., a leading ag-biologicals company and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), today announced an agreement
Read moreThe agreement supports Lavie Bio’s 2024 sales growth plan for spring wheat, durum, and barley in Canada Rehovot, Israel – December 5, 2023 — Lavie Bio Ltd., a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), a leading ag-biologicals company that develops microbiome-based, computational-driven bio-stimulant and bio-pesticide novel products, today announced a distribution
Read moreLavie Bio will offer Yalos™ (formerly Thrivus™) to farmers growing spring wheat, durum and barley across the US and Canada in 2024 Rehovot, Israel — November 28, 2023 — Lavie Bio Ltd., a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), a leading ag-biological company committed to elevating food quality, sustainability, and agricultural productivity
Read moreLAV321, discovered and optimized by Lavie Bio, delivered positive results in 2023 field trials across Europe and the US, protecting against downy mildew REHOVOT, ISRAEL – November 8, 2023 – Lavie Bio Ltd., a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), and a leading ag-biologicals company that develops microbiome-based, computational-driven bio-stimulant and bio-pesticide novel
Read moreCorteva to receive exclusive rights to further develop and commercialize Lavie Bio’s lead product candidates for fruit rot and powdery mildew fungicide biologicals REHOVOT, ISRAEL – JULY 17, 2023 – Lavie Bio Ltd., a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), and a leading ag-biologicals company that develops microbiome-based, computational driven bio-stimulant and
Read moreThe approval by the Canadian Food Inspection Agency triples Thrivus’TM sales territory Rehovot, Israel — May 24, 2023 — Lavie Bio Ltd., a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), and a leading ag-biological company focusing on improving food quality, sustainability, and agricultural productivity through the introduction of microbiome-based products, today announced it had
Read moreRehovot, Israel – March 29, 2023 — Lavie Bio Ltd. (“Lavie Bio”), a subsidiary of Evogene Ltd. (“Evogene”) (Nasdaq: EVGN, TASE: EVGN), and a leading ag-biologicals company focusing on improving food quality, sustainability, and agriculture productivity through the introduction of microbiome-based products, today is pleased to announce the appointment of Mr. Amit Noam as
Read moreRehovot, Israel – March 6, 2023 — Lavie Bio Ltd., a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), and a leading ag-biological company focusing on improving food quality, sustainability, and agriculture productivity through the introduction of microbiome-based products, today announced in that its management will be sponsoring and participating at the World Agri-Tech Conference
Read morePositive results for LAV311 and LAV321 achieved in 2022 in a series of field trials, testing for protection against bunch rot, powdery mildew and blight diseases Rehovot, Israel – February 28, 2023 — Lavie Bio Ltd., a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), and a leading ag-biological company focusing on improving food
Read moreLAV.311 is targeting fruit rots and powdery mildews fungal diseases Rehovot, Israel – October 12, 2022 — Lavie Bio Ltd., a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), and a leading ag-biological company focusing on improving food quality, sustainability, and agriculture productivity through the introduction of microbiome-based products, today announced submitting the registration package
Read moreRehovot, Israel – September 14, 2022 — Lavie Bio Ltd. (“Lavie Bio”), a subsidiary of Evogene Ltd. (“Evogene”) (Nasdaq: EVGN, TASE: EVGN), and a leading ag-biologicals company focusing on improving food quality, sustainability, and agriculture productivity through the introduction of microbiome-based products, today announced the appointment of Guri Oron as Chief Executive Officer (“CEO”) of
Read moreICL to invest $10 million in Lavie Bio Tel Aviv, Israel; August 16, 2022 – ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, and Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, announced today a multi-year,
Read moreGiven wheat global shortages and high prices, Lavie foresees continued strong demand for its bio-inoculant result™ and plans increased production for 2023 growing season Rehovot, Israel – May 11, 2022 — Lavie Bio Ltd., a subsidiary of Evogene Ltd., (NASDAQ: EVGN, TASE: EVGN) and a leading ag-biologicals company focusing on improving food quality, sustainability,
Read moreAdvancement to the pre-commercial stage follows positive results from three consecutive years of vineyard trials for fruit rot diseases Rehovot, Israel – December 14, 2021 – Lavie Bio Ltd., a leading ag-biologicals company focusing on improving food quality and agricultural productivity and sustainability through the introduction of microbiome-based products, and a subsidiary of Evogene
Read moreresult™ inoculant initially introduced for spring wheat in North Dakota, following positive four-year field trials Rehovot, Israel – November 3, 2021 — Lavie Bio Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), and a leading ag-biologicals company focusing on improving food quality and agricultural productivity and sustainability through the introduction of microbiome-based products,
Read moreCommercialization targeted for 2022 for spring wheat initially Rehovot, Israel and Berthold, ND, USA – September 29, 2021 — Lavie Bio Ltd. (Lavie), a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), and a leading ag-biologicals company focusing on improving food quality, sustainability, and agriculture productivity through the introduction of microbiome-based products, and United
Read moreThis appointment continues Lavie Bio’s advancement of its commercial pipeline, focusing on its planned product launches starting 2022 Rehovot, Israel – May 25th, 2021 – Lavie Bio Ltd., a leading ag-biologicals company focusing on improving food quality, sustainability, and agriculture productivity through the introduction of microbiome-based products, and a subsidiary of Evogene Ltd. (NASDAQ:
Read moreLAV211 bio-stimulant advancing towards anticipated 2022 commercial launch in spring wheat; Product advancement achieved in multiple programs Rehovot, Israel – December 29, 2020 – Lavie Bio Ltd. (Lavie Bio), a leading ag-biologicals company focusing on improving food quality, sustainability and agriculture productivity through the introduction of microbiome-based products, and a subsidiary of Evogene Ltd.
Read morePositive results were achieved in a series of vineyard trials for bunch rot diseases conducted in Europe and the United States Rehovot, Israel – October 29, 2020 – Lavie Bio Ltd. (Lavie Bio), a leading ag-biologicals company focusing on improving food quality, sustainability and agriculture productivity through the introduction of microbiome based products, and
Read moreLavie Bio Announces the appointment of Frederic C. Beudot, Global Portfolio Leader for Biologicals at Corteva Agriscience™, as a member of its Board of directors. With extensive experience in sales, marketing, commercial and strategy of crop protection product, Frederic will allow us to further strengthen our market and commercial focus as we progress toward product
Read moreLavie Bio announce the appointment of Prof. Naama Barkai as a member of Lavie Bio Scientific Aadvisory Board (SAB). Prof. Barkai is a professor in the departments of Molecular Genetics and Physics of Complex Systems at the Weizmann Institute of Science in Rehovot, Israel, and a member of the European Molecular Biology Organization (EMBO), the
Read moreLeading wheat bio-stimulant candidate for spring wheat, exhibiting consistent performance, advancing to ‘development stage 2’, in line with Lavie Bio’s commercialization plans for 2022 Rehovot, Israel – November 18, 2019 – Lavie Bio (Lavie), a subsidiary of Evogene (NASDAQ: EVGN, TASE: EVGN), aiming to improve food quality, sustainability and agriculture productivity through the introduction of
Read moreIn this position Jim will lead operational aspects and downstream development and commercialization efforts of Lavie Bio’s product pipeline as well as heading the Lavie Bio US site in St. Louis, Missouri. Jim previously served as VP R&D and Director of Molecular Biology and Analytics at Calyxt. Prior to Calyxt, Jim was the Director
Read moreThe nomination of industry experts is expected to support the company’s management in execution of its product development and commercialization roadmap Rehovot, Israel – September 11, 2019 – Lavie Bio, a subsidiary of Evogene (NASDAQ, TASE: EVGN), focusing on improving food quality, agricultural sustainability and productivity through the development of novel microbiome based agriculture biological
Read more